Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine in early acute respiratory distress syndrome
NCT03346681Phase 1Withdrawn
- Sponsor
- Prisma Health
- Start
- Feb 2018
- Primary completion
- Jan 2021
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of acetylcysteine inhalation solution in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Prisma Health. Primary endpoint: Ventilator days at 60 days. Planned start Feb 2018; status: withdrawn.
02
Drugs
acetylcysteine inhalation solution
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT03346681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03346681.